UroGen Pharma Ltd. — Director's Dealing 2020

Oct 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-10-01

Reporting Person: Henderson Molly (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-01	Stock Option (Right to Buy)	$19.66	A	60000	Acquired	2030-09-30	Common Stock (60000)	Direct
2020-10-01	Restricted Stock Units	$	A	15000	Acquired		Common Stock (15000)	Direct

Footnotes

F1: 1/3 of the shares underlying the stock options will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3: 1/3 of the shares underlying the restricted stock units will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023.